211 related articles for article (PubMed ID: 28058866)
1. The influence of thermal treatment and type of insoluble poly(meth)acrylates on dissolution behavior of very soluble drug from hypromellose matrix tablets evaluated by multivariate data analysis.
Kubova K; Peček D; Hasserová K; Doležel P; Pavelková M; Vyslouzil J; Muselík J; Vetchy D
Pharm Dev Technol; 2017 Mar; 22(2):206-217. PubMed ID: 28058866
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Dissolution Behavior HPMC/Eudragit
Naiserová M; Kubová K; Vysloužil J; Pavloková S; Vetchý D; Urbanová M; Brus J; Vysloužil J; Kulich P
AAPS PharmSciTech; 2018 Feb; 19(2):681-692. PubMed ID: 28971441
[TBL] [Abstract][Full Text] [Related]
3. Highly Soluble Drugs Directly Granulated by Water Dispersions of Insoluble Eudragit® Polymers as a Part of Hypromellose K100M Matrix Systems.
Mašková E; Naiserová M; Kubová K; Mašek J; Pavloková S; Urbanová M; Brus J; Vysloužil J; Vetchý D
Biomed Res Int; 2019; 2019():8043415. PubMed ID: 30949510
[TBL] [Abstract][Full Text] [Related]
4. The development of Eudragit® NM-based controlled-release matrix tablets.
Dvořáčková K; Kalėdaitė R; Gajdziok J; Rabišková M; Bajerová M; Muselík J; Lažauskas R; Pečiūra R; Bernatonienė J
Medicina (Kaunas); 2012; 48(4):192-202. PubMed ID: 22836292
[TBL] [Abstract][Full Text] [Related]
5. Poly vinyl acetate and ammonio methacrylate copolymer as unconventional polymer blends increase the mechanical robustness of HPMC matrix tablets.
Ali R; Dashevsky A; Bodmeier R
Int J Pharm; 2017 Jan; 516(1-2):3-8. PubMed ID: 27818241
[TBL] [Abstract][Full Text] [Related]
6. Film-coated matrix mini-tablets for the extended release of a water-soluble drug.
Mohamed FA; Roberts M; Seton L; Ford JL; Levina M; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2015 Apr; 41(4):623-30. PubMed ID: 24564797
[TBL] [Abstract][Full Text] [Related]
7. A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.
Huang S; O'Donnell KP; Keen JM; Rickard MA; McGinity JW; Williams RO
AAPS PharmSciTech; 2016 Feb; 17(1):106-19. PubMed ID: 26335416
[TBL] [Abstract][Full Text] [Related]
8. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets.
Dave VS; Fahmy RM; Bensley D; Hoag SW
Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339
[TBL] [Abstract][Full Text] [Related]
9. The performance of HPMC matrix tablets using various agglomeration manufacturing processes.
Košir D; Vrečer F
Drug Dev Ind Pharm; 2017 Feb; 43(2):329-337. PubMed ID: 27739880
[TBL] [Abstract][Full Text] [Related]
10. Effect of hydrophobic inclusions on polymer swelling kinetics studied by magnetic resonance imaging.
Gajdošová M; Pěček D; Sarvašová N; Grof Z; Štěpánek F
Int J Pharm; 2016 Mar; 500(1-2):136-43. PubMed ID: 26780121
[TBL] [Abstract][Full Text] [Related]
11. The influence of polymer content on early gel-layer formation in HPMC matrices: The use of CLSM visualisation to identify the percolation threshold.
Mason LM; Campiñez MD; Pygall SR; Burley JC; Gupta P; Storey DE; Caraballo I; Melia CD
Eur J Pharm Biopharm; 2015 Aug; 94():485-92. PubMed ID: 26143369
[TBL] [Abstract][Full Text] [Related]
12. Reducing Burst Release Effect of Freely Water-Soluble Drug Incorporated into Gastro-Floating Formulation Below HPMC Threshold Concentration Through Interpolymer Complex.
Choiri S; Sulaiman TNS; Rohman A
AAPS PharmSciTech; 2019 May; 20(5):196. PubMed ID: 31123934
[TBL] [Abstract][Full Text] [Related]
13. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Maboos M; Yousuf RI; Shoaib MH; Nasiri I; Hussain T; Ahmed HF; Iffat W
Lipids Health Dis; 2018 Jun; 17(1):136. PubMed ID: 29885655
[TBL] [Abstract][Full Text] [Related]
14. (Meth)acrylate copolymers of Eudragit® type in oral tablet technology.
Naiserová M; Kubová K; Vysloužil J; Bernatoniene J; Brokalakis I; Vetchý D
Ceska Slov Farm; 2019; 68(5):183-197. PubMed ID: 31896262
[TBL] [Abstract][Full Text] [Related]
15. Determining the polymer threshold amount for achieving robust drug release from HPMC and HPC matrix tablets containing a high-dose BCS class I model drug: in vitro and in vivo studies.
Klančar U; Baumgartner S; Legen I; Smrdel P; Kampuš NJ; Krajcar D; Markun B; Kočevar K
AAPS PharmSciTech; 2015 Apr; 16(2):398-406. PubMed ID: 25331194
[TBL] [Abstract][Full Text] [Related]
16. Prolonged-release minitablets with carbamazepine - preliminary observations in vitro.
Dzajkowska M; Hanna K; Anna M; Maja S; Dagmara D; Anna S; Malgorzata S
J Pharm Pharmacol; 2017 Apr; 69(4):471-479. PubMed ID: 28000299
[TBL] [Abstract][Full Text] [Related]
17. Studies in preparation and evaluation of pH-independent sustained-release matrix tablets of verapamil HCl using directly compressible Eudragits.
Gohel MC; Patel TP; Bariya SH
Pharm Dev Technol; 2003; 8(4):323-33. PubMed ID: 14601957
[TBL] [Abstract][Full Text] [Related]
18. Influence of pH Modulation on Dynamic Behavior of Gel Layer and Release of Weakly Basic Drug from HPMC/Wax Matrices, Controlled by Acidic Modifiers Evaluated by Multivariate Data Analysis.
Mašková E; Kubová K; Vysloužil J; Pavloková S; Vetchý D
AAPS PharmSciTech; 2017 May; 18(4):1242-1253. PubMed ID: 27474035
[TBL] [Abstract][Full Text] [Related]
19. Release Adjustment of Two Drugs with Different Solubility Combined in a Matrix Tablet.
Chaerunisaa AY; Ali R; Dashevskiy A
AAPS PharmSciTech; 2019 Mar; 20(4):142. PubMed ID: 30874996
[TBL] [Abstract][Full Text] [Related]
20. Interpolyelectrolyte complexes of Eudragit® EPO with hypromellose acetate succinate and Eudragit® EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery.
Jeganathan B; Prakya V
AAPS PharmSciTech; 2015 Aug; 16(4):878-88. PubMed ID: 25591951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
